AlphaCentric Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

AlphaCentric Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-80,000	Closed	-$457K	–	231
2024 Q2	$457K	Hold	80,000	–	–	0.34%	84
2024 Q1	$401K	Buy	80,000 +30,000	+60%	+$204K	0.24%	91
2023 Q4	$450K	Hold	50,000	–	–	0.3%	77
2023 Q3	$389K	Hold	50,000	–	–	0.22%	107
2023 Q2	$484K	Sell	50,000 -27,500	-35%	-$285K	0.27%	98
2023 Q1	$849K	Sell	77,500 -275,000	-78%	-$2.42M	0.59%	63
2022 Q4	$1.52M	Buy	352,500 +193,000	+121%	+$1.12M	1.5%	12
2022 Q3	$1.2M	Buy	+159,500	New	+$1.38M	1.23%	17
2021 Q3	–	Sell	-25,000	Closed	-$324K	–	198
2021 Q2	$324K	Sell	25,000 -10,000	-29%	-$127K	0.09%	84
2021 Q1	$454K	Buy	35,000 +15,000	+75%	+$218K	0.15%	49
2020 Q4	$277K	Buy	20,000 +15,900	+388%	+$231K	0.12%	45
2020 Q3	$60K	Buy	+4,100	New	+$59.4K	0.03%	94

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AlphaCentric Advisors's AUPH Position: Q3 2024 in Review

AlphaCentric Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2024, closing a stake of 80,000 shares — an estimated $457K sold.

AlphaCentric Advisors first reported a position in AUPH in Q3 2020 and held it in 12 quarters. The position peaked at $1.52M in Q4 2022. 183 funds tracked by Wall St. Rank hold AUPH as of Q3 2024.

AlphaCentric Advisors reported no remaining Aurinia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
AlphaCentric Advisors sold 80,000 Aurinia Pharmaceuticals shares in Q3 2024, an estimated $457K.
AlphaCentric Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 12 quarters.
AlphaCentric Advisors's Aurinia Pharmaceuticals position peaked at $1.52M in Q4 2022.
183 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.